Change the order, improve the outcome, potentially extend survival.
For patients whose cancer has traveled to the brain, the sequence of treatment has long followed a familiar logic: remove the tumor first, then irradiate what remains. A multi-center study from Wake Forest University and Atrium Health Levine Cancer Institute, drawing on data from 404 patients worldwide, quietly challenges that assumption — finding that delivering stereotactic radiosurgery before surgery, rather than after, may significantly reduce recurrence, limit the spread of cancer cells, and spare patients from some of radiation's most damaging side effects. In medicine, as in much of human experience, the order in which we do things turns out to matter more than we imagined.
- Metastatic brain tumors arrive with a heavy toll — headaches, seizures, weakness, lost balance — and the standard treatment sequence has long left too many patients facing recurrence rates as high as 39 percent within two years.
- The core disruption is a reversal of assumption: researchers found that radiating the tumor while it is still intact allows for far greater precision, and that surgery itself may scatter cancer cells into the brain's surrounding fluid, seeding further disease.
- Preoperative SRS cut two-year cavity recurrence to 13.7 percent and reduced meningeal disease to 5.8 percent — numbers that stand in sharp contrast to the 16–21 percent spread rates seen with the conventional postoperative approach.
- The research also revealed that outcomes can be further refined based on surgical completeness, cancer type, and technique — suggesting this is not a blunt instrument but one that can be carefully calibrated.
- A national phase 3 randomized clinical trial is now enrolling patients to deliver the definitive verdict, with the potential to rewrite the standard of care for one of oncology's most consequential diagnoses.
When cancer spreads to the brain from the lungs, the breast, or elsewhere, it arrives as a metastatic brain tumor — and with it come headaches, seizures, weakness, and lost balance. For patients with a limited number of these tumors, surgery combined with stereotactic radiosurgery, a form of radiation so precisely aimed it can destroy a tumor while sparing surrounding tissue, offers a path forward. For decades, the standard has been to operate first, then radiate. A team from Wake Forest University School of Medicine and Atrium Health Levine Cancer Institute asked a simple but consequential question: what if you reversed the order?
Analyzing data from 404 patients across multiple centers worldwide, the researchers tracked recurrence in the surgical cavity, spread of cancer cells to the brain's surrounding fluid, and adverse radiation effects. The results were striking. At two years, cavity recurrence stood at 13.7 percent — compared to 22 to 39 percent with the standard postoperative approach. Meningeal disease occurred in just 5.8 percent of patients, versus 16 to 21 percent in the literature. Radiation side effects appeared in only 5 percent.
The explanation, according to lead researcher Roshan Prabhu, is partly visual and partly biological. An intact tumor is easier to target precisely. And surgery itself may scatter cancer cells into the fluid surrounding the brain — a risk that preoperative radiation appears to reduce by treating the tumor before it is disturbed. The study, published in JAMA Oncology, also found that outcomes varied based on how completely the tumor was removed, the cancer type, and the surgical technique — suggesting the approach can be tailored rather than applied uniformly.
Postoperative SRS remains the current standard of care, but the evidence has grown compelling enough to launch a national phase 3 randomized clinical trial now enrolling patients at multiple sites. That trial will determine whether reversing the sequence of treatment becomes the new default — and for patients living with metastatic brain tumors, the answer could meaningfully reshape what comes next.
When cancer spreads to the brain from somewhere else in the body—the lungs, the breast, elsewhere—it arrives as a metastatic brain tumor, and it arrives with weight. Headaches. Seizures. A loss of balance. Weakness that creeps in. For patients with a limited number of these tumors, surgery combined with a focused radiation technique called stereotactic radiosurgery can help push back against these symptoms and buy time.
Stereotactic radiosurgery, despite its name, is not surgery at all. It's a form of radiation so precisely aimed that it can destroy a tumor while leaving the surrounding healthy brain tissue largely untouched. For decades, the standard approach has been to operate first—to cut out the tumor—and then deliver the radiation afterward, in what's called postoperative SRS. But a growing body of research suggests the order matters. What if you radiated first, while the tumor was still intact and easier to see, and then operated? A team from Wake Forest University School of Medicine and Atrium Health Levine Cancer Institute set out to test this reversal.
The researchers gathered data on 404 patients from multiple centers around the world who had received preoperative SRS followed by surgery. They tracked three outcomes: whether the tumor came back in the surgical cavity, whether cancer cells spread to the fluid surrounding the brain (a condition called meningeal disease), and whether patients suffered adverse effects from the radiation itself—swelling, inflammation, or radiation necrosis, a painful condition where tissue dies from lack of blood supply. The numbers they found were striking. At two years, the cavity recurrence rate was 13.7 percent. Meningeal disease occurred in 5.8 percent of patients. Symptomatic radiation side effects appeared in just 5 percent. When the researchers compared these figures to what the medical literature reports for the standard postoperative approach, the gap widened. Postoperative SRS typically produces recurrence rates between 22 and 39 percent, meningeal disease rates between 16 and 21 percent, and adverse radiation effects in 7 to 18 percent of patients.
Why would changing the order of treatment make such a difference? Roshan Prabhu, the radiation oncologist who led the study, points to a simple fact: when the tumor is still there, intact, the doctors can see exactly what they're aiming at. The radiation can be more precise. There's also evidence that the act of surgery itself—cutting into the tumor and removing it—can scatter cancer cells into the fluid that bathes the brain and spinal cord, creating a pathway for the disease to spread. By irradiating first, while the tumor is whole, that risk appears to diminish.
The study also identified specific factors that predicted better or worse outcomes after preoperative SRS: how completely the surgeon removed the tumor, what type of cancer it was, how many radiation sessions the patient received, and the surgical technique used. These details matter because they suggest the approach is not one-size-fits-all; it can be refined, tailored, optimized.
Postoperative SRS remains the standard of care, the default choice in most hospitals. But this research, published in JAMA Oncology, suggests that simply reversing the sequence of treatments—radiation before surgery instead of after—could reduce recurrence, lower the risk of spread, and spare patients from some of the long-term damage that radiation can cause. Prabhu noted that the finding is straightforward: change the order, improve the outcome, potentially extend survival. The evidence is compelling enough that a national phase 3 randomized clinical trial is now enrolling patients at multiple sites to directly compare the two approaches. The trial will be the definitive test, the moment when preoperative SRS either becomes the new standard or remains a promising alternative. For patients with metastatic brain tumors, the answer could reshape how they are treated.
Citas Notables
By simply changing the sequencing of treatment, it can potentially improve outcomes and increase survival.— Roshan Prabhu, M.D., radiation oncologist at Atrium Health Levine Cancer Institute
La Conversación del Hearth Otra perspectiva de la historia
Why does the order of treatment matter so much? It seems like the same two procedures either way.
Because timing changes what the radiation oncologist can see. With an intact tumor, the target is clear. Once you cut it out, the tumor is gone—but the surgical cavity remains, and that's what you're trying to prevent from regrowing. You're aiming at an absence.
And the spread to the brain fluid—why does surgery increase that risk?
When you operate, you're handling the tumor, moving it, removing it. That mechanical disruption can shed cancer cells into the cerebrospinal fluid. If you've already irradiated the tumor, it's been weakened, contained. The cells that might escape are fewer and already damaged.
So preoperative SRS is essentially a way to sterilize the tumor before you touch it.
That's one way to think about it. You're also giving yourself a clearer picture of what needs to be treated. The tumor hasn't been disturbed yet. The anatomy is as it actually exists in the patient's body.
The recurrence rates are dramatically lower—13.7 percent versus 22 to 39 percent. That's a real difference in people's lives.
It is. And it's not just recurrence. The adverse effects are lower too. Fewer people experience the long-term swelling and tissue damage that can come from radiation. You're reducing harm while improving control.
Is there a reason this hasn't been standard practice already?
Inertia, partly. Postoperative SRS became the standard because it was the first approach that worked well enough. Once a practice becomes standard, it takes strong evidence to change it. This study provides that evidence, but it's not a head-to-head trial yet. That's what the phase 3 trial will do.